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Available online 6 January 2016Stimulation of vascular calcium-sensing receptors (CaSRs) is reported to induce both constrictions and relaxa-
tions. However, cellular mechanisms involved in these responses remain unclear. The present study investigates
the effect of stimulating CaSRs on vascular contractility and focuses on the role of the endothelium, nitric oxide
(NO) and K+ channels in these responses. In wire myography studies, increasing [Ca2+]o from 1 mM to 6 mM
induced concentration-dependent relaxations of methoxamine pre-contracted rabbit mesenteric arteries.
[Ca2+]o-induced relaxations were dependent on a functional endothelium, and were inhibited by the negative
allosteric CaSR modulator Calhex-231. [Ca2+]o-induced relaxations were reduced by inhibitors of endothelial
NO synthase, guanylate cyclase, and protein kinase G. CaSR activation also induced NO production in freshly iso-
lated endothelial cells (ECs) in experiments using the ﬂuorescent NO indicator DAF-FM. Pre-treatment with in-
hibitors of large (BKCa) and intermediate (IKCa) Ca2+-activated K+ channels (iberiotoxin and charybdotoxin),
and Kv7 channels (linopirdine) also reduced [Ca2+]o-induced vasorelaxations. Increasing [Ca
2+]o also activated
IKCa currents in perforated-patch recordings of isolatedmesenteric artery ECs. These ﬁndings indicate that stim-
ulation of CaSRs induces endothelium-dependent vasorelaxationswhich aremediated by two separate pathways
involving production of NO and activation of IKCa channels. NO stimulates PKG leading to BKCa activation in vas-
cular smooth muscle cells, whereas IKCa activity contributes to endothelium-derived hyperpolarisations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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IKCa1. Introduction
Stimulation of plasmalemmal Ca2+-sensing receptors (CaSRs) by an
increase in the extracellular Ca2+ concentration ([Ca2+]o) is involved in
maintaining plasma Ca2+ homeostasis through regulation of parathyroid
hormone from the parathyroid gland, intestinal Ca2+ absorption, and
renal Ca2+excretion [1]. It is also apparent that CaSRs are expressed in tis-
sues not involved in plasma Ca2+ homeostasis, including the
Cardiovascular system [2]. In the presence of closely regulated plasma
Ca2+ levels, regulation of CaSRs is considered possible, as interstitial and
localised [Ca2+]o is likely to vary sufﬁciently at the surface of cells [1,3].
In the vasculature, CaSRs are expressed in perivascular nerves,
endothelial cells (ECs), and vascular smooth muscle cells (VSMCs),
and stimulation of these CaSRs is proposed to regulate vascular tone
[2,4]. Consequently, CaSRs and their associated cellular mechanisms
are considered novel targets for controlling blood pressure. In addition,
stimulation of CaSRs in the vasculature may also explain potentialrg).
. This is an open access article underCardiovascular risk following Ca2+ supplements [5]. To date there is lit-
tle consensus on the function of CaSRs in the vasculature, with ﬁndings
suggesting that stimulation of CaSRs induces both vasoconstrictions and
vasorelaxations through diverse cellular mechanisms [2,4].
Stimulation of CaSRs on perivascular nerves is proposed to evoke
synthesis and release of nitric oxide (NO) or vasoactive lipids from
pre-synaptic terminals, which activate large conductance Ca2+-
activated K+ channels (BKCa) in adjacent VSMCs that induces mem-
brane hyperpolarisation and subsequent vasorelaxation [6–9]. In ad-
dition, activation of CaSRs on ECs is reported to generate NO [10–13]
or induce activation of intermediate conductance Ca2+-activated K+
channels (IKCa) [14–16], which act as endothelium-derived relaxation
or hyperpolarisation factors to also induce vasorelaxations. In contrast,
CaSR-induced activation of Gq- and MAPK kinase-mediated pathways
in VSMCs are linked to vasoconstriction [17,18] and cell proliferation
[19–22] respectively. Taken together, theseﬁndings indicate that the ef-
fect of stimulating CaSRs in the vasculature is likely to be multifaceted.
However, many of the studies examining the functional role of
vascular CaSRs have used calcimimetic compounds rather than endoge-
nous CaSR ligands to activate the receptor. Importantly, these agentsthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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for example by inhibiting voltage-gated Ca2+ channels, by directly induc-
ing endothelial nitric oxide generation, and by stimulating the opening of
VSMC K+ channels [9,11], thereby inducing vasorelaxations of pre-
contracted vessels in a CaSR-independent manner. Accordingly, the
mechanisms regulating vascular tone that are CaSR-mediated remain un-
clear. Moreover there is little information on the contribution of the pro-
posed CaSR-mediated pathways in the same vascular preparation.
Therefore the present work investigates CaSR-mediated effects induced
by increasing [Ca2+]o, an endogenous CaSR activator, and also focuses
on the contribution of the endothelium, NO production and K+ channels
in rabbitmesenteric arteries. In experiments usingwiremyography,ﬂuo-
rescence microscopy and electrophysiological techniques, we show that
CaSRs are expressed in ECs and VSMCs, and that stimulation of CaSRs in-
duces endothelium-dependent relaxations of methoxamine-induced
pre-contracted vessels through production of NO and activation of IKCa
channels.
2. Methods
2.1. Cell and vessel segment preparation
Male New Zealand White rabbits (2.5–3 kg) were killed by intrave-
nous injection of sodium pentobarbitone (120 mgkg−1) in accordance
with Schedule I of the UK Animals Scientiﬁc Procedures Act, 1986.
Second-order branches of rabbit superior mesenteric artery were dis-
sected and cleaned of adherent tissue in physiological salt solution
(PSS) containing (mM): NaCl 126, KCl 6, Glucose 10, HEPES 11, MgCl2
1.2, and CaCl2 1.5, with pH adjusted to 7.2 with 10 M NaOH. Following
dissection, vessels were either cut into 2 mm segments for wire
myography studies or were enzymatically dispersed to obtain freshly
isolated ECs. To isolate single ECs, vessels were washed in PSS contain-
ing 50 μM [Ca2+]o for 5 min at 37 °C and placed in collagenase solution
(1 mgmL−1) for 15 min at 37 °C. The vessels were then triturated in
fresh PSS and the cell-containing solutionwas collected and centrifuged
for 1 min at 1000 rpm. The supernatant was removed and the cells re-
suspended in fresh PSS containing 0.75mM [Ca2+]o, plated onto cover-
slips, and left at 4 °C for 1 h before use. To obtain isolated VSMCs, a sim-
ilar techniquewas used except that initially the endotheliumwas gently
removed from vessels with a cotton bud, and then the vessels were
exposed to an enzyme solution containing collagenase (1 mgmL−1)
and protease (0.2 mgmL−1) in 50 μM [Ca2+]o PSS for 15 min.
2.2. Isometric tension recordings
Effects of stimulatingCaSRs on vascular tonewere investigated using
wiremyography. Vessel segments of 2mm in lengthweremounted in a
wire myograph (Model 610 M; Danish Myo Technology, Aarhus,
Denmark) and equilibrated for 30 min at 37 °C in 5 mL of gassed (95%
O2/5% CO2) Krebs–Henseleit solution of the following composition
(mM): NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, CaCl2 2,
D-glucose 10. The mean resting diameter of the vessel segments was
422 ± 19 μm. Once mounted, vessel segments were then normalized
to 90% of the internal circumference predicted to occur under a
transmural pressure of 100 mmHg23. Mean vessel tensions were
5.3 ± 0.06 mN (n = 52, 253 vessel segments) in endothelium-intact
vessels, and 5.2 ± 0.21mN (n= 8, 18 vessel segments) in endothelium
removed vessels after normalisation. After normalisation, vessels were
left for 10min andwere then challengedwith 60mMKCl for 5min. En-
dothelium integrity was then assessed by stably pre-contracting vessels
with 10 μMmethoxamine. Preliminary experiments demonstrated that
10 μM induced ~80% of the maximum methoxamine-induced contrac-
tion (data not shown). This was followed by the addition of 10 μM
Carbachol (CCh) and vessels in which CCh-induced relaxations
were N90% of pre-contracted tone were designated as having a func-
tional endothelium. When required, endothelium was removed byrubbing the intima with a human hair, and CCh-induced relaxations
of b10% of pre-contracted tone indicated successful removal. Vessel
segments were incubated for 30 min in fresh Krebs solution contain-
ing 1 mM CaCl2 and then pre-contracted with 10 μM methoxamine,
300 nM U46619, or 60 mM KCl as required. This was followed by
cumulative additions of CaCl2, increasing [Ca2+]o from 1 to 6 mM in
the presence of inhibitors tested or their respective vehicles. All inhibi-
tors were added to the vessel segments 30 min before the construction
of concentration–response curves to [Ca2+]o. For each experiment, ve-
hicle controls were performed using vessel segments from the same an-
imal. All relaxant responses are expressed as percentage relaxation of
tension induced by either 10 μM methoxamine, 300 nM U46619, or
60 mM KCl. Data points on all graphs are mean values and error bars
represent S.E.M. For each experiment n = number of animals, with at
least 3–4 vessel segments used from each animal. Responses to increas-
ing [Ca2+]o were analysed by 2-way ANOVA followed by Bonferroni
post hoc tests. p b 0.05 was taken as statistically signiﬁcant. Bonferroni
comparisons are shownabove the graph data pointswhereby: *p b 0.05,
**p b 0.01, ***p b 0.001, ****p b 0.0001 vs. controls. EC50 and Emax values
were also calculated and compared with Student's t-test. Statistical
analysis and graphs were made using Graphpad Prism 6 software
(GraphPad Software, Inc., San Diego, CA, USA).
2.3. Immunocytochemistry
Freshly dispersed ECs/VSMCs were ﬁxed onto borosilicate coverslips
with 4% paraformaldehyde (Sigma-Aldrich, Gillingham, UK) for 10 min,
washed 4 timeswith phosphate-buffered saline (PBS), and permeabilised
with PBS containing 0.1% Triton X-100 for 20 min at room temperature.
Cells were then washed 4 times with PBS and incubated with PBS con-
taining 1% bovine serum albumin (BSA) for 1 h at room temperature.
The cells were then incubated overnight at 4 °C with mouse anti-CaSR
antibody (1:200) and either goat anti-PECAM-1 (1:200) for ECs or
goat anti-α-actin (1:100) for VSMCs in PBS containing 1% BSA. In con-
trol experiments, cells were incubated without primary antibodies.
The cells were then washed 4 times with PBS and incubated with sec-
ondary antibodies conjugated to a ﬂuorescent probe for 1 h (Alexa
Fluor 546-conjugated donkey anti-mouse antibody (1:500) and Alexa
Fluor 488-conjugated donkey anti-goat antibody (1:500). Unbound sec-
ondary antibodieswere removed bywashingwith PBS, and nuclei were
labelledwith 4′,6-diamidino-2-phenylindole (DAPI)mountingmedium
(Sigma-Aldrich). Cells were imaged using a Zeiss LSM 510 laser scan-
ning confocal microscope (CaSRl Zeiss, Jena, Germany). Excitation was
produced by 543 nm or 488 nm lasers and delivered to the specimen
via a Zeiss Apochromat ×63 oil-immersion objective. Emitted ﬂuores-
cence was captured using LSM 510 software (release 3.2; CaSRl Zeiss).
Two-dimensional images cut horizontally through the middle of the
cells were captured and raw confocal imaging data processed using
Zeiss LSM 510 software. Final images were produced using PowerPoint
(Microsoft XP; Microsoft, Richmond, WA, USA).
2.4. Nitric oxide imaging
ECs were placed in a sterilised 96-well plate and left for 1 h at 4 °C.
Cells were loaded with the nitric oxide ﬂuorescent dye DAF-FM
diacetate (1 μM), incubated at 4 °C for 20 min and then washed with
PSS containing 1 mM [Ca2+]o. The cells were then left for another
30 min at 4 °C to allow complete de-esteriﬁcation of intracellular
diacetate. Inhibitors tested or their respective vehicles were also
added at this point. Changes in ﬂuorescence following 5 min of CaSR
stimulation with 6 mM [Ca2+]o were captured using a Zeiss Axiovert
200 M Inverted microscope and processed and analysed using AxioVi-
sion SE64 Software (Rel. 4.9.1; CaSRl Zeiss). 10 μM CCh was used as a
positive control. Additional experiments were CaSRried out to investi-
gate the origins of the baseline ﬂuorescence observed in ECs loaded
with DAF-FM diacetate. In these studies, ﬂuorescence changes were
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spective vehicles. Changes in ﬂuorescence were quantiﬁed by selecting
a cell as a region of interest (ROI) and comparing ﬂuorescence levels
within the ROI before and after the experimental protocols and analysed
using unpaired Student's t-test with p b 0.05 considered signiﬁcant.
Figures and analysis were made using Graphpad Prism 6 (GraphPad
Software, Inc., San Diego, CA, USA).
2.5. Electrophysiology
Whole-cell and perforated-patch conﬁgurations of the patch clamp
technique were used to record K+ conductances. Recordings were
made with an Axopatch 200B ampliﬁer (Axon Instruments, Union
City, CA, USA) at room temperature (20–23 °C). Currents were ﬁltered
at 1 kHz (−3 dB, low-pass 8-pole Bessel ﬁlter, Frequency Devices
model LP02; Scensys, Aylesbury, UK) and sampled at 5 kHz (Digidata
1322 A and pCLAMP 9.0 software; Molecular Devices, Sunnydale, CA,
USA). Currents were evoked by either dialysing cells with a pipette
solution containing 3 μM free Ca2+ or by bath applying 6 mM
[Ca2+]o in whole-cell or perforated-patch recordings, respectively.
Additional whole-cell recordings were made with a patch pipette so-
lution containing no added Ca2+. Current/voltage relationships (I/V)
were obtained by applying a 200 ms voltage ramp from−100 mV to
+100 mV every 30 s from a holding potential of−60 mV. IKCa cur-
rents were calculated from the decrease in current produced by
charybdotoxin (CbTx) and the presence of SKCa currents was calcu-
lated by any further decrease in current induced by co-application
of apamin. I/V relationship are from mean data ± S.E.M., with each
point from n = 6 patches and at least 3 animals. Data were analyzed
using unpaired Student's t-test with p b 0.05 considered signiﬁcant.
Figures and analysis were made using MicroCal Origin 6.0 software
(MicroCal Software, Northampton, MA, USA). The external bathing
solution for both whole-cell and perforated-patch recordings
contained as previously used [24] (mM): NaCl 134, KCl 6, Glucose
10, HEPES 10, MgCl2 1, CaCl2 1 (adjusted to pH 7.4 with 10 M
NaOH). For whole-cell recordings, the pipette solution contained
(mM): KCl 134, HEDTA 5, HEPES 10, MgCl2 5.53 (1 mM free Mg2+)
and CaCl2 0.207 (3 μM free Ca2+) (pH 7.2). The amounts of MgCl2
and CaCl2 added were determined using EqCal software (Biosoft,
Cambridge, UK). For experiments using a pipette solution containing
no added Ca2+, CaCl2 was omitted. For perforated-patch recordings
the pipette solution contained (mM): K-aspartate 110, KCl 30, NaCl
10, HEPES 10, MgCl2 1, pH 7.2 with 10 M NaOH, and amphotericin
(200 μgmL−1).
2.6. Materials
Mouse anti-CaSR (SC-47741), goat anti-PECAM-1 (SC-1506), goat
anti-α-actin (SC-1616), and secondary antibodies were obtained from
Santa Cruz Biotechnology (Dallas, TX, USA). All other materials were
purchased from Sigma-Aldrich (Sigma Chemical Co., Poole, UK) or
Tocris (Tocris Biosciences, Bristol, UK). Drugs were dissolved in distilled
water or dimethyl sulfoxide (DMSO).
3. Results
3.1. Stimulation of CaSRs induces endothelium-dependent vasorelaxation of
rabbit mesenteric arteries
In our initial experiments, we investigated the functional role of
CaSRs in rabbit mesenteric arteries by studying the effect of increasing
[Ca2+]o on pre-contracted tone evoked by 10 μM methoxamine.
Fig. 1A shows that increasing [Ca2+]o from 1 mM to 6 mM induced
concentration-dependent relaxations of rabbit mesenteric artery vessel
segments compared to time-matched vehicle controls. Fig. 1A and B re-
veal that almost complete relaxation of pre-contracted tone wasachieved with 6 mM [Ca2+]o, and that physiological plasma [Ca2+]o
levels (1–2 mM) relaxed pre-contracted tone between 30 and 50%.
(EC50 ~ 2.2 mM [Ca2+]o and Emax ~ 96%, Table 1).
We next studied if removal of a functional endotheliumhad an effect
on [Ca2+]o-induced relaxations. Fig. 1A demonstrates that removal of a
functional endothelium, determined by the absence of CCh-evoked re-
laxations of pre-contracted tone (see Methods), completely abolished
[Ca2+]o-induced relaxations. Instead, Fig. 1A and B reveal that in the ab-
sence of a functional endothelium increasing [Ca2+]o between 1 mM
and 6 mM produced a concentration-dependent potentiation of pre-
contracted tone, with 6 mM [Ca2+]o increasing contractility by over
50%. There was no difference in the mean amplitude of pre-contracted
tone induced by 10 μM methoxamine between vessel segments with
functional endothelium-intact compared to those with functional
endothelium-removed (6.5 ± 0.6 mN, n = 8 vs 9.1 ± 2.1 mN respec-
tively, n = 8 animals with 3–4 vessel segments from each animal,
p N 0.05). These data indicate that stimulation of CaSRs exerts
vasorelaxant and vasoconstrictor actions via endothelium- and vascular
smooth muscle-dependent processes, respectively. In a separate exper-
iment, the samephenomenonwas demonstrated using a different vaso-
constrictor agent to pre-contract the vessels, namely the thromboxane
receptor agonist U46619, with increases in [Ca2+]o increases in
[Ca2+]o evoking concentration-dependent vasorelaxations that were
abolished with the removal of the endothelium (Supplementary
Figure S1).
To examine if [Ca2+]o-induced relaxations of methoxamine pre-
contracted tone were mediated by stimulation of CaSRs, we pre-
treated vessel segments with Calhex-231, a negative allosteric
modulator of CaSRs [25]. Fig. 2A shows that 3 μM Calhex-231
inhibited [Ca2+]o-induced relaxations compared to time-matched
vehicle controls. In control experiments, 3 μM Calhex-231 had no
effect on CCh-induced relaxations of pre-contracted tone (Supple-
mentary Figure S2) indicating that this calcilytic did not affect the
general ability of vessel segments to relax. Consistent with our
ideas for an involvement of CaSRs, Fig. 2B shows that CaSRs were
expressed in freshly isolated rabbit mesenteric ECs and VSMCs
using immunocytochemistry.
These results provide clear evidence that stimulation of CaSRs in-
duces a profound endothelium-dependent relaxation.
3.2. Generation of NO in endothelial cells contributes to CaSR-mediated
relaxations
A role for NO has been proposed to mediate actions of CaSRs in
the vasculature [10–12], and therefore we wished to explore if NO con-
tributed to the CaSR-induced endothelium-dependent vasorelaxations
described above. We ﬁrst studied the effect of L-NAME, an endothelial
NO synthase (eNOS) inhibitor, on [Ca2+]o-induced relaxations of
pre-contracted tone. Fig. 3A shows that pre-treatment with
300 μM L-NAME produced a pronounced inhibition of [Ca2+]o-
induced vasorelaxations. It is well-established that NO induces
vasorelaxations through a pathway involving guanylate cyclase (GC),
production of cGMP, and stimulation of protein kinase G (PKG) activity,
which subsequently regulates contractile mechanisms in vascular
smooth muscle [26]. Fig. 3B and C show that pre-treatment with the
GC inhibitor, ODQ (10 μM), and the PKG inhibitor KT5823 (1 μM), also
produced marked inhibition of [Ca2+]o-induced relaxations of pre-
contracted tone. Previous studies have shown that PKG may act to
suppress EDH mechanisms and that inhibition with KT5823 can evoke
signiﬁcant EDH-mediated vasorelaxations [27]. As Supplementary
Figure S3 shows, 1 μM KT5823 induced endothelium-dependent relax-
ations of pre-contracted tonewhichwere inhibited by co-application of
the IKCa blocker charybdotoxin (CbTX) and the SKCa blocker apamin. It
is therefore possible that KT5823-mediated vasorelaxations may have
contributed to an underestimation of the inhibitory action of KT5823
on CaSR-mediated responses.
Fig. 1. Effect of [Ca2+]o on pre-contracted tone of rabbit mesenteric arteries. (A) Representative traces showing the effect of [Ca2+]o on pre-contracted tone induced by 10 μM
methoxamine (MO). The left record shows that MO induces a stable vasoconstriction in the presence of 1 mM [Ca2+]o, whilst the middle and right records show the effect of
increasing [Ca2+]o from 1 mM to 6 mM on endothelium-intact and endothelium-removed vessels respectively. (B) Mean data showing the effect of [Ca2+]o on MO-induced pre-
contraction tone. Each point is from n = 8 animals, with at least n = 3 vessel segments per animal. **p b 0.01, ***p b 0.001.
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NO production, we studied the effect of increasing [Ca2+]o on NO
generation in freshly isolated mesenteric artery ECs using the cell-
permeable ﬂuorescent NO indicator DAF-FM. Fig. 4A and B demon-
strates that increasing [Ca2+]o from 1 mM to 6 mM enhanced basal
ﬂuorescence by over 30% compared to time-matched vehicle con-
trols, and that these responses were reduced by pre-treatment
with 3 μM Calhex-231 and 300 μM L-NAME. Fig. 4C and D also
shows that basal ﬂuorescent levels recorded in 1 mM [Ca2+]o were
reduced by 3 μM Calhex-231 and 300 μM L-NAME. Positive control
experiments revealed that CCh-evoked increases in ﬂuorescence in
1 mM [Ca2+]o which were unaffected by 3 μM Calhex-231 but asTable 1
The effect of the various inhibitors tested on [Ca2+]o-induced vasorelaxations.
EC50 (mM) Emax (%) n
Controls 2.2 ± 0.04 96 ± 3.4 8
-Endothelium − − 8
+ Calhex-231 (μM) 4 ± 0.51⁎⁎⁎⁎ 54.6 ± 4.6⁎⁎ 4
+ L-NAME (300 μM) 4.1 ± 0.01⁎⁎⁎⁎ 8.3 ± 11⁎⁎⁎⁎ 7
+ ODQ (10 μM) 3.1. ± 0.59⁎⁎⁎ 30.8 ± 14⁎⁎⁎ 4
+ KT5283 (1 μM) 4.5 ± 0.42⁎⁎⁎ 53.4 ± 12⁎⁎ 4
+ IbTx (100 nM) 4.3 ± 0.21⁎⁎⁎⁎ 51.9 ± 5.1⁎⁎⁎ 4
+ IbTx (100 nM) + CbTx (100 nM) 5.1 ± 0.03⁎⁎⁎⁎ 15 ± 11.7⁎⁎⁎⁎ 5
+ IbTX (200 nM) 4.1 ± 0.34⁎⁎⁎⁎ 45 ± 7.2⁎⁎⁎ 5
+ Apamin (100 nM) 2.1 ± 0.01 93 ± 3.3 4
+ Linopirdine (10 μM) 2.1 ± 0.22 72 ± 3.3⁎⁎ 4
+Indomethacin(10 μM) 2.3 ± 0.05 92 ± 3.5 5
+Glibenclamide 2.1 ± 0.31 91 ± 4.6 4
+L-NAME (300 μM) + CbTx(100 nM) − − 5
EC50 and Emax values were comparedwith Student's t-test vs. corresponding controls. n=
animals used, with at least 3 vessel segments per animal.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
⁎⁎⁎⁎ p b 0.0001.has been shown previously [28], were inhibited by 300 μM L-NAME
(Supplementary Figure S4).
These results provide strong evidence that stimulation of CaSRs
evokes NO production in mesenteric artery ECs leading to PKG-
dependent vasorelaxations.
3.3. Voltage-gated and Ca2+-activated K+ channels also contribute to
CaSR-mediated vasorelaxations
It is well recognised that IKCa and SKCa channels expressed in ECs
have pivotal roles in mediating endothelium-derived hyperpolarisations
which couple to relaxation of VSMCs [29,30], and IKCa channel activity
is also linked to CaSR-mediated hyperpolarisations and vasorelaxations
[14–16]. It is also possible that other K+ channels such as Kv7 and KATP
channels expressed in VSMCs may be involved in mediating CaSR-
induced vasorelaxations [31,32]. Therefore we examined the effect of
BKCa, IKCa, SKCa, Kv7, andKATP channel inhibitors on [Ca2+]o-induced re-
laxations of pre-contracted tone.
Fig. 5A shows that pre-treatment with 100 nM iberiotoxin (IbTX),
a selective BKCa inhibitor, markedly reduced [Ca2+]o-induced
vasorelaxations. Since charybdotoxin (CbTX) blocks BKCa and IKCa
channels we investigated the role of IKCa channel activity by pre-
treating vessel segments with 100 nM IbTX and 100 nM CbTX. Fig. 5A
shows that co-application of these two agents induced an additional in-
hibition of [Ca2+]o-mediated relaxations compared to IbTX alone. In
fact, in the presence of IbTx and CbTx increasing [Ca2+]o between
1 mM and 5 mM induced an increase in pre-contracted tone (Fig. 5A).
To conﬁrm that the additive inhibitory effect of CbTX and IbTX co-
application was not due to enhanced BKCa blockade, a control experi-
ment was performed in which vessels were pre-treated with 200 nM
IbTX. Importantly, this did not have any additional inhibitory effect on
[Ca2+]o-induced vasorelaxations compared with vessels pre-treated
with 100 nM IbTX (Fig. 5A).
Fig. 2. Relaxant effect of [Ca2+]o on pre-contracted tone involve CaSRs. (A) Mean data showing that relaxations of pre-contracted tone induced by increasing [Ca2+]o from 1mM to 6mM
are reduced by pre-treatmentwith 3 μMCalhex-231. Each point is from n=4 animals, with at least n=3 segments per animal. **p b 0.01, ***p b 0.001. (B) Immunocytochemistry images
showing that CaSRs are expressed in ECs and VSMCs. PECAM-1 and α-actin are selective markers for ECs and VSMCs respectively. DAPI stains the cell nucleus.
79H.Z.E. Greenberg et al. / Vascular Pharmacology 80 (2016) 75–84Pre-treatment with 10 μM linopirdine, a selective Kv7 blocker, only
reduced vasorelaxations produced by 6 mM [Ca2+]o, whilst 100 nM
apamin and 10 μM glibenclamide, blockers of SKCa and KATP channels
respectively, and 10 μM indomethacin, a cycloxygenase inhibitor,
had no effect on [Ca2+]o-induced relaxations of pre-contracted tone
(Fig. 5B).
These ﬁndings suggest that BKCa- and IKCa-mediated
hyperpolarisations of VSMCs may make essential contributions to
CaSR-evoked vasorelaxations. We tested this proposal by studying
the effect of [Ca2+]o on pre-contracted tone induced by 60 mM KCl
in vessel segments containing a functional endothelium. In these
conditions, the membrane potential of VSMCs is clamped at a ﬁxed
membrane potential of about −20 mV, evoking vasoconstrictions
that are entirely mediated by voltage-dependent calcium-channels
(Supplementary Figure S5). Fig. 5C shows that increasing [Ca2+]oFig. 3.Effect ofNO–GC–PKGpathway inhibitors on [Ca2+]o-induced relaxations of pre-contracte
the eNOS inhibitor L-NAME (300 μM), (B) the guanylate cyclase inhibitor ODQ (10 μM) and (C
segments per animal. **p b 0.01, ***p b 0.001.from 1 mM to 6 mM failed to induce relaxations in KCl pre-contracted
vessels, and instead, increasing [Ca2+]o potentiated contractility.
In a ﬁnal series of functional experiments, we investigated the com-
bined effects of NO, and BKCa and IKCa channels on [Ca2+]o-induced re-
laxations by using L-NAME to inhibit eNOS and CbTX to block BKCa and
IKCa channels. As expected, Fig. 5D illustrates that co-application of
300 μM L-NAME and 100 nM CbTX abolished [Ca2+]o-induced relaxa-
tions of pre-contracted tone. In fact, in the presence of L-NAME and
CbTX responses to [Ca2+]o were similar to those induced in the absence
of a functional endothelium (Fig. 1A and B), with [Ca2+]o inducing a
marked potentiation of pre-contracted tone.
These results suggest that activation of BKCa and IKCa channel in-
duces hyperpolarisations which have signiﬁcant roles in mediating
CaSR-induced relaxations in rabbit mesenteric arteries. Since BKCa and
IKCa channels are selectively expressed in VSMCs and ECs respectively,d tone. [Ca2+]o-induced relaxations of pre-contracted toneweremarkedly inhibited by (A)
) the PKG inhibitor KT5823 (1 μM). Each point is from n = 4 animals, with at least n = 3
Fig. 4. Effects of [Ca2+]o on NO production in ECs measured using DAF-FM ﬂuorescence. (A) and (B) show original images and mean data showing that increasing [Ca2+]o from 1 mM to
6 mM enhanced basal ﬂuorescence which was inhibited by pre-treatment with 3 μM Calhex-231 or 300 μM L-NAME. (C) and (D), representative images and mean data illustrating that
basal ﬂuorescence in 1 mM [Ca2+]o was inhibited by Calhex-231 and L-NAME. n = at least 50 cells from n = 4 animals. ** p b 0.01, ***p b 0.001.
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mediated pathway described above whereas CaSRs activate IKCa chan-
nels via an unknown mechanism.
3.4. Stimulation of CaSRs activates IKCa currents
To provide further evidence that stimulation of CaSRs induces acti-
vation of IKCa channels in ECs, we carried out electrophysiological re-
cordings using whole-cell and perforated patch conﬁgurations of the
patch clamp technique from freshly isolated rabbit mesenteric artery
ECs.
Fig. 6A and B show that in the absence of Ca2+ in the patch pipette
solution, application of voltage ramps from −100 mV to +100 mV
from a holding potential of−60 mV evoked a linear mean whole-cell
current which reversed near to the equilibrium potential for K+ ions
(EK is−80 mV), and was inhibited by the non-selective voltage-gated
K+ channel blocker tetraethylammonium (TEA). Fig.6C and D shows
that inclusion of 3 μM free Ca2+ in the patch pipette solution evoked a
much largermeanwhole-cell current, which displayed inward rectiﬁca-
tion at positive potentials, and reversed close to EK. Mean whole-cell
currents induced by 3 μM free Ca2+ were reduced by 100 nM CbTX
and further inhibited by co-applications of 100 nM CbTX with 100 nM
apamin. In these latter conditions, the mean whole-cell current resem-
bled the linear current induced in the absence of Ca2+. These ﬁndings
show that rabbit mesenteric ECs express functional native IKCa and
SKCa channels as previously described in other native ECs [24,33–37].
Fig. 7A and B demonstrate that increasing [Ca2+]o from 1 mM to
6 mM evoked a mean macroscopic current using the perforated patch
conﬁguration which had similar inward rectiﬁcation at positive poten-
tials and reversal potential to the mean whole-cell current induced by3 μM free Ca2+. Fig. 7A and B shows that themean [Ca2+]o-induced cur-
rentwas inhibited by application of 3 μMCalhex-231 butwas not affect-
ed by 300 μM L-NAME. Moreover, Fig. 7C and D shows that the mean
[Ca2+]o-induced current was reduced by 100 nM CbTX but was unaf-
fected by 100 nM apamin. These results indicate that stimulation of
CaSRs evokes native IKCa currents in rabbit mesenteric artery ECs via
a NO-independent pathway.
4. Discussion
This study shows that stimulation of CaSRs by increasing [Ca2+]o in-
duces endothelium-dependent relaxations of pre-contracted rabbit mes-
enteric arteries. We propose that these CaSR-induced vasorelaxations are
mediated by two separate pathways initiated in ECs: NO generation lead-
ing to stimulation of a PKG-mediated pathway and opening of BKCa chan-
nels in VSMCs, and stimulation of IKCa channel activity which is likely to
induce endothelium-derived hyperpolarisations.
4.1. CaSR-mediated relaxations are endothelium-dependent
Increasing [Ca2+]o between 1 mM and 6 mM induced a
concentration-dependent relaxation of pre-contracted tone in rabbit
mesenteric arteries, which was markedly inhibited by the calcilytic
Calhex-231 and abolished by removal of a functional endothelium.
In contrast, increasing [Ca2+]o potentiated pre-contracted tone in
endothelium-removed vessel segments. As predicted from these
ﬁndings, CaSRs were expressed at the plasmamembrane of freshly iso-
latedmesenteric artery ECs andVSMCs. These results suggest that in the
endothelium-intact artery, CaSR-mediated vasorelaxations are the
dominant physiological phenomenon.
Fig. 5. Effects of K+ channel blockers on [Ca2+]o-induced relaxations of pre-contracted tone. The effects of pre-treating vessel segments with (A) IbTX (100 nM or 200 nM), apamin
(100 nM), and CbTX together with IbTX (both 100 nM) and (B) linopirdine (10 μM), indomethacin (10 μM), or glibenclamide (10 μM) on [Ca2+]o-induced relaxations of pre-
contracted tone. (C) Effect of [Ca2+]o on 60 mM KCl-induced pre-contracted tone in endothelium-intact vessel segments. (D) Effect of L-NAME (300 μM) and CbTX (100 nM) on
[Ca2+]o-induced relaxations of pre-contracted tone. The effect of [Ca2+]o on endothelium-removed vessel segments (Fig. 1A) is also shown for comparison. #p b 0.05, *p b 0.05,
**p b 0.01, ***p b 0.001.
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that CaSR mRNA and protein are expressed in ECs [10,12,14,16,38,39]
and VSMCs [12,18–22,24,40–42], and that stimulation of these
CaSRs induces endothelium-dependent relaxations [12–14,16] and
endothelium-independent vasoconstrictions [17,18], respectively.
Increasing [Ca2+]o has also been shown to induce CaSR-mediated
biphasic effects on pre-contracted tone, with an initial contraction
followed by relaxation [9,43]. CaSRs are also reported to be expressed on
perivascular nerves, and stimulation of these receptors is proposed to in-
duce the release of a nerve derived hyperpolarising factor (NDHF)which
activates BKCa channels in VSMCs to induce hyperpolarisation and vaso-
relaxation [6,7,44–46]. The present study indicates a signiﬁcant role for
the endothelium in mediating CaSR-induced vasorelaxations, which
suggests that perivascular nerves are unlikely to be involved. It is not
known why there are differences between the present work and these
earlier ﬁndings, although recent evidence indicates that capsaicin used
to provide evidence for the involvement of perivascular nerves may
also induce vasorelaxations through activation of TRPV1 channels
expressed in ECs [47,48], and the identity of the proposed NDHF is cur-
rently unknown. Moreover, there may be species differences in CaSR-
mediated vascular effects.
4.2. NO production contributes to CaSR-induced endothelium-dependent
relaxations
[Ca2+]o-induced vasorelaxations of pre-contracted tone were
reduced by inhibitors of eNOS, GC, PKG, and BKCa channels. These
data provide strong evidence that stimulation of CaSRs induces the
well-characterised NO–GC–PKG signalling cascade system, which cou-
ples to opening of BKCa channels in VSMCs leading to hyperpolarisationand vasorelaxation. A direct stimulatory action of NO on BKCa channels
may also contribute to CaSR-mediated vasorelaxations [49,50]. Further
evidence that NO production plays a pivotal role in CaSR-mediated
vasorelaxations was provided by experiments showing that increasing
[Ca2+]o induced NO production in isolated ECs loaded with ﬂuorescent
NO indicator DAF-FM, whichwas inhibited by Calhex-231 and L-NAME.
An interesting observation was that basal DAF-FM ﬂuorescence record-
ed in the presence of 1 mM [Ca2+]o was also inhibited by Calhex-231
and L-NAME. This provides evidence that physiological plasma [Ca2+]o
levels may mediate resting vascular tone through stimulation of CaSRs
and induce basal production of NO.
Our data are consistent with earlier data indicating a potential role
for NO in CaSR-mediated responses in ECs and in other cell types
[10–13,51,52]. In cultured human aortic endothelial cells, Ziegelstein
et al. [10] demonstrated a CaSR-mediated rise in intracellular [Ca2+]
and subsequent NO generation, but only when CaSRs were stimulat-
ed with spermine and not with other CaSR agonists such as Ca2+,
Gd3+, or neomycin. In contrast, this study was able to demonstrate
Ca2+-induced CaSR activation and resulting NO production. Poten-
tially, this difference may reﬂect variability in CaSR-signalling be-
tween cultured ECs and freshly isolated native ECs. In a later study
using the calcimimetic AMG 073, Smajilovic et al. [11] observed
dose-dependent vasorelaxations of pre-contracted rat aorta, with a
signiﬁcant L-NAME-sensitive component present. Importantly, how-
ever, the authors did not rule out whether this response was CaSR-
mediated, and other studies have indeed demonstrated that several
calcimimetic compounds have CaSR-independent effects that may
explain their vascular actions. For example, the calcimimetic R-568
was shown to directly induce NO production in cultured human umbil-
ical vein ECs without involving CaSR activation, and the calcimimetic
Fig. 6. IKCa and SKCa currents in freshly isolated ECs. (A) Representative trace and (B)mean I/V relationship ofwhole-cell patch recordings showing a TEA-sensitive current present in the
absence of [Ca2+]i, (C) and (D) show that inclusion of 3 µM free Ca2+ in the patch pipette solution evoked currents which were inhibited by CbTX (100 nM) and apamin (300 nM). All
points are from n = 6 patches from at least n = 3 animals.
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clinically-used mimetic cinacalcet and calindol have also been shown
to directly block voltage-gated calcium channels and activate VSMCFig. 7. [Ca2+]o-induced IKCa currents in freshly isolated ECs. (A) Representative trace and (B) t
from 1 mM to 6 mM evoked currents which were inhibited by Calhex-231 (3 µM) but were un
inhibited by the addition of CbTX (100 nM) but were unaffected by apamin (300 nM). All poinK+ channels [9]. Accordingly, our data using the endogenous CaSR
ligand in freshly isolated native ECs offer important insights into the
functional role of vascular CaSRs in vascular tone regulation.he mean I/V relationships of perforated-patch recordings showing that increasing [Ca2+]o
affected by L-NAME (300 µM). (C) and (D) show that [Ca2+]o-induced currents were also
ts are from n = 6 patches from at least n = 3 animals.
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relaxations
Co-application of 100nM IbTX togetherwith 100nMCbTXproduced
a markedly greater inhibition of [Ca2+]o-induced vasorelaxations
compared to 100 nM IbTX alone. IbTX is a selective BKCa blocker
whereas CbTX blocks both BKCa and IKCa, and therefore this addi-
tive effect is most likely due to CaSR-mediated activation of IKCa
channels which are expressed in ECs but not VSMCs. In addition,
increasing [Ca2+]o from 1 mM to 6 mM evoked macroscopic K+
conductances, which had similar properties to previously described
IKCa channels in vascular ECs [23] and were inhibited by Calhex-
231 and CbTX. Previous studies have used TRAM-34 to block IKCa
channels and thereby demonstrate IKCa involvement in endothelial
responses [14,15,53,54]. However, this study did not use TRAM-34
since it also inhibits non-selective cation channels [55], which may
be important for generating the observed CaSR responses. The
present work and others [24,33] also show that SKCa channel activ-
ity is present in ECs, although it seems unlikely that SKCa channels
have a role in CaSR-mediated vasorelaxations as the selective SKCa
blocker apamin had no effect on CaSR-induced vasorelaxations or
K+ channel activity. The selective activation of IKCa over SKCa
following CaSR activation potentially reﬂects the functional co-
localisation of IKCa and CaSRs in the EC plasma membrane [14],
although the precise mechanism responsible for CaSR-induced
IKCa activation remains unclear and is the subject of ongoing
investigation.
Co-application of L-NAME and CbTX produced an additional in-
hibitory effect on CaSR-induced relaxations compared to applica-
tions of L-NAME alone. Moreover, L-NAME did not affect CaSR-
induced IKCa channel activity in isolated ECs. These ﬁndings indicate
that CaSR-mediated vasorelaxations are unlikely to involve interac-
tions between NO-mediated pathways and IKCa channels, which
are consistent with earlier ﬁndings showing that NO is involved in
activating SKCa but not IKCa channels in ECs [56]. It was apparent
that following inhibition of NO- and IKCa-mediated pathways, in-
creasing [Ca2+]o potentiated pre-contracted tone, with a similar
magnitude to that observed with removal of a functional endothelium.
This further indicates that CaSR-induced endothelium-dependent
vasorelaxations are mainly produced through NO- and IKCa channel-
mediated pathways. In future studies it will be interesting to investi-
gate if the contribution of these two pathways to CaSR-mediated
vasorelaxations differs at different [Ca2+]o, and with different vascu-
lar beds and order branches.
Our results also indicate a role for Kv7 channels in CaSR-mediated
relaxations at higher [Ca2+]o, as the pan Kv7 blocker linopirdine pro-
duce a small by signiﬁcant reduction in these responses. Heteromeric
Kv7.4/7.5 channels and other unidentiﬁed Kv channels expressed in
VSMCs are reported to mediate relaxations induced by NO [27,57–60].
It is therefore possible that activation of Kv7.4/7.5 channels via a
CaSR-mediated NO-mediated pathway may contribute to the observed
vasorelaxations.
4.4. Possible signiﬁcance of ﬁndings
The present work clearly indicates that endothelium-dependent
vasorelaxations mediated by CaSRs contribute to the regulation of
vascular tone. Indeed even at plasma Ca2+ levels of 1–2 mM, CaSR-
induced vasorelaxations occur, suggesting that endothelial CaSRs may
sense free Ca2+ ions in the blood as they pass over the luminal EC sur-
face. Furthermore, active Ca2+ extrusion from adjacent contracting vas-
cular myocytes, may cause the localised [Ca2+]o to be much higher
within the tight space between the two cell layers than it is within
the circulating blood [1,3]. This paracrine Ca2+ signalling may then
help to amplify the contribution of vascular CaSRs to vascular tone reg-
ulation [62].5. Conclusions
Stimulation of CaSRs induces endothelium-dependent vaso-
relaxations which are mediated by two separate pathways involving
production of NO and activation of IKCa channels. NO stimulates PKG
leading to BKCa activation in vascular smooth muscle cells, whereas
IKCa activity contributes to endothelium-derived hyperpolarisations.
Funding
This work was supported by a British Heart Foundation PhD Stu-
dentship for H. Z. E. Greenberg (FS/13/10/30021 to A.P.A); and by the
Biotechnology and Biological Sciences Research Council (BB/J007226/1
to A.P.A).
Conﬂict of interest
None declared.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.vph.2016.01.001.
References
[1] E.M. Brown, R.J. MacLeod, Extracellular calcium sensing and extracellular calcium
signalling, Physiol. Rev. 81 (2001) 239–297.
[2] S. Smajilovic, S. Yano, R. Jabbari, J. Tfelt-Hansen, The calcium-sensing receptor and
calcimimetics in blood pressure modulation, Br. J. Pharmacol. 164 (2011) 884–893.
[3] A.M. Hofer, Another dimension to calcium signalling: a look at extracellular calcium,
J. Cell Sci. 118 (2005) 855–862.
[4] A.H. Weston, A. Geraghty, I. Egner, G. Edwards, The vascular extracellular calcium-
sensing receptor: an update, Acta Physiol. 203 (2011) 127–137.
[5] I.R. Reid, Cardiovascular effects of calcium supplements, Nutrients 5 (2013) 2552–
2529.
[6] R.D. Bukoski, K. Bian, Y. Wang, M. Mupanomunda, Perivascular sensory nerve Ca2+
receptor and Ca2+-induced relaxation of isolated arteries, Hypertension 30 (1997)
1431–1439.
[7] N. Ishioka, R.D. Bukoski, A role for N-arachidonylethanolamine (anandamide) as the
mediator of sensory nerve-dependent Ca2+-induced relaxation, J. Pharmacol. Exp.
Ther. 289 (1999) 245–250.
[8] E.M. Awumey, S.K. Hill, D.I. Diz, R.D. Bukoski, Cytochrome P-450 metabolites of 2-
arachidonoylglycerol play a role in Ca2+-induced relaxation of rat arteries, Am. J.
Physiol. Heart Circ. Physiol. 294 (2008) H2363–H2370.
[9] P. Thakore, W.-S.V. Ho, Vascular actions of calcimimetics: role of Ca2+-sensing re-
ceptors versus Ca2+ inﬂux through L-type Ca2+ channels, Br. J. Pharmacol. 162
(2011) 749–762.
[10] R.C. Ziegelstein, Y. Xiong, C. He, Q. Hu, Expression of a functional extracellular
calcium-sensing receptor in human aortic endothelial cells, Biochem. Biophys. Res.
Commun. 342 (2006) 153–163.
[11] S. Smajilovic, M. Sheykhzade, H.N. Holmegard, S. Hanuso, J. Tfelt-Hansen,
Calcimimetric, AMG, induces relaxation on isolated rat aorta, Vasc. Pharmacol. 47
(2007) 222–228.
[12] A.E. Loot, I. Pierson, T. Syzonenko, A. Elgheznawy, V. Randriamboavonjy, A. Zivkovic,
et al., Ca2+-sensing receptor cleavage by calpain partially accounts for altered vascu-
lar reactivity in mice fed a high-fat diet, J. Cardiovasc. Pharmacol. 61 (2013)
528–535.
[13] E.M. Awumey, L.E. Bridges, C.L. Williams, D.I. Diz, Nitric-oxide synthase knockout
modulates Ca2+-sensing receptor expression and signalling in mouse mesenteric
arteries, J. Pharmacol. Exp. Ther. 346 (2013) 38–47.
[14] A.H. Weston, M. Absi, D.T. Ward, J. Ohanian, R.H. Dodd, P. Dauban, et al., Evidence in
favour of a calcium-sensing receptor in arterial endothelial cells: studies with
calindol and calhex-231, Circ. Res. 97 (2005) 391–398.
[15] K.A. Dora, N.T. Gallagher, A. McLeish, C.J. Garland, Modulation of endothelial cell
KCa3.1 channels during endothelium-derived hyperpolarisation factor signalling in
mesenteric resistance arteries, Circ. Res. 102 (2008) 1247–1255.
[16] A.H. Weston, M. Absi, E. Harno, A.R. Geraghty, D.T. Ward, M. Ruat, et al., The expres-
sion and functional of Ca2+-sensing receptors in rat mesenteric artery; comparative
studies using a model of type II diabetes, Br. J. Pharmacol. 154 (2008) 652–662.
[17] K. Wonneberger, M.A. Scoﬁeld, P. Wangemann, Evidence for a calcium-sensing re-
ceptor in the vascular smooth muscle cells of the spiral modiolar artery, J. Membr.
Biol. 175 (2000) 203–212.
[18] G.-W. Li, Q.-S. Wang, J.-H. Hao, W.-J. Xing, J. Guo, H.-Z. Li, et al., The functional ex-
pression of extracellular calcium-sensing receptor in rat pulmonary artery smooth
muscle cells, J. Biomed. Sci. 18 (2011) 16.
84 H.Z.E. Greenberg et al. / Vascular Pharmacology 80 (2016) 75–84[19] S. Smajilovic, J.L. Hansen, T.H.E. Christoffersen, E. Lewin, S.P. Sheokh, E.F. Terwilliger,
et al., Extracellular calcium sensing in rat aortic vascular smooth muscle cells,
Biochem. Biophys. Res. Commun. 348 (2006) 1215–1223.
[20] G. Molostvov, S. James, S. Fletcher, J. Bennett, H. Lehnert, R. Bland, et al., Extracellular
calcium-sensing receptor is functionally expressed in human artery, Am. J. Physiol.
Renal Physiol. 293 (2007) F946–F955.
[21] G. Molostvov, S. Fletcher, R. Bland, D. Zehnder, Extracellular calcium-sensing recep-
tor mediated signalling is involved in human vascular smooth muscle cell prolifera-
tion and apoptosis, Cell. Physiol. Biochem. 22 (2008) 413–422.
[22] G.-W. Li, W.-J. Xing, S.-Z. Bai, J.-H. Hao, J. Guo, H.-Z. Li, et al., The calcium-sensing re-
ceptor mediates hypoxia-induced proliferation of rat pulmonary artery smooth
muscle cells through MEK1/ERK1,2 and PI3K pathways, Basic Clin. Pharmacol.
Toxicol. 108 (2010) 185–193.
[23] M.J. Mulvany, W. Halpern, Contractile properties of small arterial resistance vessels
in spontaneously hypertensive and normotensive rats, Circ. Res. 41 (1977) 19–26.
[24] J. Ledoux, A.D. Bonev, M.T. Nelson, Ca2+-activated K+ channels in murine endothe-
lial cells: block by intracellular calcium and magnesium, J. Gen. Physiol. 131 (2008)
125–135.
[25] C. Petrel, A. Kessler, F. Maslah, P. Dauban, R.H. Dodd, D. Rognan, et al., Modelling and
mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator
of the extracellular Ca2+-sensing receptor, J. Biol. Chem. 278 (2003) 494874–49494.
[26] S.H. Francis, J.L. Busch, J.D. Corbin, D. Sibley, cGMP-dependent protein kinases and
cGMP phosphodiestereases in nitric oxide and cGMP action, Pharmacol. Rev. 62
(2010) 525–563.
[27] K.A. Dora, C.J. Garland, H.Y. Kwan, X. Yao, Endothelial cell protein kinase G inhibits
release of EDHF through a PKG-sensitive cation channel, Am. J. Physiol. Circ. Physiol.
280 (2001) H1272–H1277.
[28] J. Pittner, R. Liu, R. Brown, M. Wolgast, A.E. Persson, Visualization of nitric oxide pro-
duction and intracellular calcium in juxtamedullary afferent arteriolar endothelial
cells, Acta Physiol. Scand. 179 (2003) 309–317.
[29] G. Edwards, M. Feletou, A.H. Weston, Endothelium-derived hyperpolarising factor
and associated pathways: synopsis, Pﬂugers Arch. 459 (2010) 863–879.
[30] C.J. Garland, C.R. Hiley, K.A. Dora, EDHF: spreading the inﬂuence of the endothelium,
Br. J. Pharmacol. 164 (2011) 839–852.
[31] J.E. Brayden, Functional roles of KATP channels in vascular smooth muscle, Clin. Exp.
Pharmacol. Physiol. 29 (2002) 312–316.
[32] T.A. Jepps, S.P. Olesen, I.A. Greenwood, One man's side effect is another man's ther-
apeutic opportunity: targeting Kv7 channels in smooth muscle disorders, Br. J.
Pharmacol. 168 (2013) 19–27.
[33] M.P. Burnham, R. Bychkov, M. Feletou, G.R. Richards, P.M. Vanhoutte, A.H. Weston,
et al., 2002. Characterization of an apamin-sensitive small-conductance Ca2+-
activated K+ channel in porcine coronary artery endothelium: relevance to EDHF,
Br. J. Pharmacol. 135 (2002) 1133–1143.
[34] R. Bychkov, M.P. Burnham, G.R. Richards, G. Edwards, A.H. Weston, M. Feletou, et al.,
Characterization of a charybdotoxin-sensitive intermediate conductance Ca2+-
activated K+ channel in porcine coronary endothelium: relevance to EDHF, Br. J.
Pharmacol. 137 (2002) 1346–1354.
[35] I. Eichler, J. Wibawa, I. Grgic, A. Knorr, S. Brakemeier, A.R. Pries, et al., Selective block-
ade of endothelial Ca2+-activated small- and intermediate-conductance K+-
channels suppresses EDHF-mediated vasodilation, Br. J. Pharmacol. 138 (2003)
594–601.
[36] H. Si, W.T. Heyken, S.E. Wolﬂe, M. Tysiac, R. Schubert, I. Grgic, et al., Impaired
endothelium-derived hyperpolarizing factor-mediated dilations and increased
blood pressure in mice deﬁcient of the intermediate-conductance Ca2+-activated
K+ channel, Circ. Res. 99 (2006) 537–544.
[37] M.S. Taylor, A.D. Bonev, T.P. Gross, D.M. Eckman, J.E. Brayden, C.T. Bond, et al.,
Altered expression of small-conductance Ca2+-activated K+ (SK3) channels modu-
lates arterial tone and blood pressure, Circ. Res. 93 (2003) 124–131.
[38] R. Berra Romani, A. Raqeeb, U. Laforenza, M.F. Scafﬁno, F. Moccia, J.E. Avelino-Cruz,
et al., Cardiac microvascular endothelial cells express a functional Ca2+-sensing re-
ceptor, J. Vasc. Res. 46 (2009) 73–82.
[39] M. Bonomini, A. Giardinelli, C. Morabito, S. Di Silvestre, M. Di Cesare, N. Di Pietro,
et al., Calcimimetic R-568 and its enantiomer S-568 increase nitric oxide release in
human endothelial cells, PLoS ONE 7 (2012) e30682.
[40] M.U. Alam, J.P. Kirton, F.L. Wilkinson, E. Towers, S. Sinha, M. Rouhi, et al., Calciﬁca-
tion is associated with loss of functional calcium-sensing receptor in vascular
smooth muscle cells, Cardiovasc. Res. 81 (2009) 260–268.
[41] J.Y. Chow, C. Estrema, T. Orneles, X. Dong, K.E. Barrett, H. Dong, Calcium-sensing re-
ceptor modulates extracellular Ca2+ entry via TRPC-encoded receptor-operatedchannels in human aortic smooth muscle cells, Am. J. Physiol. Cell Physiol. 301
(2011) C461–C468.
[42] A. Yamamura, Q. Guo, H. Yamamura, A.M. Zimnicka, N.M. Pohl, K.A. Smith, et al.,
Ca2+-sensing receptor function in idiopathic pulmonary arterial hypertension,
Circ. Res. 111 (2012) 469–481.
[43] J. Ohanian, K.M. Gatﬁeld, D.T. Ward, V. Ohanian, Evidence for a functional calcium-
sensing receptor that modulates myogenic tone in rat subcutaneous small arteries,
Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H1756–H1762.
[44] M. Mupanomunda, Y. Wang, R.D. Bukoski, Effects of chronic sensory denervation on
Ca2+-induced relaxation of isolated mesenteric resistance arteries, Am. J. Physiol.
274 (1998) H1655–H1661.
[45] Y. Wang, R.D. Bukoski, Distribution of the perivascular nerve Ca2+ receptor in rat ar-
teries, Br. J. Pharmacol. 125 (1998) 1397–1404.
[46] R.D. Bukoski, S. Bátkai, Z. Járai, Y.Wang, L. Offertaler,W.F. Jackson, et al., CB1 receptor
antagonist SR141716A inhibits Ca2+-induced relaxation in CB1 receptor-deﬁcient
mice, Hypertension 39 (2002) 251–257.
[47] I. Poblete, M. Orliac, R. Briones, E. Adler-Graschinsky, J. Huidobro-Toro, Anandamide
elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation
in the rat arterial mesenteric bed, J. Physiol. 568 (2005) 539–551.
[48] D. Yang, Z. Luo, S. Ma, W.Wong, L. Ma, J. Zhong, et al., Activation of TRPV1 by dietary
capsaicin improves endothelium-dependent vasorelaxation and prevents hyperten-
sion, Cell Metab. 12 (2010) 130–141.
[49] V.M. Bolotina, S. Najibi, J.J. Palacino, P.J. Pagano, R.A. Cohen, Nitric oxide directly ac-
tivates calcium-dependent potassium channels in vascular smooth muscle, Nature
368 (1994) 850–853.
[50] D.K. Mistry, C.J. Garland, Nitric oxide (NO)-induced activation of large conductance
Ca2+-dependent K+ channels (BK(Ca)) in smooth muscle cells isolated from the rat
mesenteric artery, Br. J. Pharmacol. 124 (1998) 1131–1140.
[51] I. Dal Pra, A. Chiarini, E. Nemeth, U. Armato, J.Whitﬁeld, Roles of Ca2+ and the Ca2+-
sensing receptor (CASR) in the expression of inducible NOS (nitric oxide synthase)-
2 and its BH4 (tetrahydrobiopterin)-dependent activation in cytokine-stimulated
adult human astrocytes, J. Cell. Biochem. 96 (2005) 428–438.
[52] J. Tfelt-Hansen, A. Ferreira, S. Yano, D. Kanuparthi, J.R. Romero, E.M. Brown, et al.,
Calcium-sensing receptor activation induces nitric oxide production in H-500
Leydig cancer cells, Am. J. Physiol. Endocrinol. Metab. 288 (2005) E1206–E1213.
[53] H. Wulff, M.J. Miller, W. Haensel, S. Grissner, M.D. Cahalan, K.G. Chandy, Design of
potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+
channel, IKCa1: a potential immunosuppressant, Proc. Natl. Acad. Sci. U. S. A. 97
(2000) 8151–8156.
[54] H. Wulff, A. Kolski-Andreaco, A. Sankaranarayanan, J.M. Sabatier, V. Shakkottai,
Modulators of small- and intermediate-conductance calcium-activated potassium
channels and their therapeutic indications, Curr. Med. Chem. 14 (2007) 1437–1457.
[55] T. Schilling, C. Eder, TRAM-34 inhibits nonselective cation channels, Pﬂugers Arch.
454 (2007) 559–563.
[56] A. McNeish, S. Sandow, C. Neylon, M. Chen, K.A. Dora, C.J. Garland, Evidence for in-
volvement of both IKCa and SKCa channels in hyperpolarizing responses of the rat
middle CaSRebral artery, Stroke 37 (2006) 1277–1282.
[57] F. Lovren, C. Triggle, Nitric oxide and sodium nitroprusside-induced relaxation of the
human umbilical artery, Br. J. Pharmacol. 131 (2000) 521–529.
[58] A. McNeish, F. Altayo, C.J. Garland, Evidence both L-type and non-L-type voltage-
dependent calcium channels contribute to cerebral artery vasospasm following
loss of NO in the rat, Vasc. Pharmacol. 53 (2010) 151–159.
[59] L. Ooi, S. Gigout, L. Pettinger, N. Gamper, Triple cysteine module within M-type K+
channels mediates reciprocal channel modulation by nitric oxide and reactive oxy-
gen species, J. Neurosci. 33 (2013) 6041–6046.
[60] J.B. Stott, V. Barrese, T.A. Jepps, E.V. Leighton, I.A. Greenwood, Contribution of Kv7
channels to natriuretic peptide mediated vasodilation in normal and hypertensive
rats, Hypertension 65 (2015) 676–682.
[61] S.G. Straub, B. Kornreich, R.E. Oswald, E.F. Nemeth, G.W. Sharp, The calcimimetic
R-467 potentiates insulin secretion in pancreatic beta cells by activation of a non-
speciﬁc cation channel, J. Biol. Chem. 275 (2000) 18777.
[62] M. Schepelmann, P. Yarova, I. Lopez-Fernandez, T. Davies, S. Brennan, P. Edwards, A.
Aggarwal, J. Graca, K. Rietdorf, V. Matchkov, R. Fenton, W. Chang, M. Krssak, A.
Stewart, K. Broadley, D.Ward, S. Price, D. Edwards, P. Kemp, D. Riccardi, The vascular
Ca2+-sensing receptor regulates blood vessel tone and blood pressure, Am. J.
Physiol. Cell Physiol. (2015) ajpcell.00248.2015.
